Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.21.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenues    
Royalty $ 0 $ 240
Product 25,530 304
Total Revenues 25,530 544
Operating Expenses    
Research and development 3,873,079 3,894,966
General and administrative 1,810,160 1,703,522
Sales and marketing 427,401 273,954
Total Operating Expenses 6,110,640 5,872,442
Operating Loss (6,085,110) (5,871,898)
Other Income (Expenses)    
Grant income 0 7,924
Interest income 1,721 38,414
Interest expense (42,181) (33,779)
Total Other Income (Expenses) (40,460) 12,559
Net Loss (6,125,570) (5,859,339)
Net Loss attributable to Non-Controlling Interest 9,424 9,567
Net Loss attributable to VolitionRx Limited Stockholders (6,116,146) (5,849,772)
Other Comprehensive Income (Loss)    
Foreign currency translation adjustments 134,133 373,926
Net Comprehensive Loss $ (5,991,437) $ (5,485,413)
Net Loss Per Share - Basic and Diluted $ (0.12) $ (0.14)
Weighted Average Shares Outstanding    
- Basic and Diluted 50,928,742 41,197,125